Clinical characteristics of HER2-low stage I triple-negative breast cancer

Tomomi Sanomachi,Hitomi Okuma Shumiyoshi,Rui Kitadai,Asuka Kawachi,Shu Yazaki,Momoko Tokura,Motoko Arakaki,Ayumi Saito,Shosuke Kita,Kasumi Yamamoto,Aiko Maejima,Yuki Kojima,Tadaaki Nishikawa,Kazuki Sudo,Tatsunori Shimoi,Emi Noguchi,Yasuhiro Fujiwara,Akihiko Suto,Kan Yonemori

ANNALS OF ONCOLOGY（2023）

引用 0|浏览3

暂无评分

摘要

In stage I triple-negative breast cancer (TNBC), postoperative adjuvant therapy and follow-up are performed according to risk factors. Accumulation of effective clinical trial data is still scarce for this population, and further examination of the prognostic and predictive factors is necessary. In recent years, it has been reported that HER2-low cases (1+/2+ and ISH negative) have different prognosis compared to HER2 0 cases, and practice changes have been made for this population in the metastatic setting. However, the risk of recurrence and risk factors in this HER2-low population for Stage I TNBC have yet to be investigated.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要